Additionally, CRISPR-KO of NKG2A can improve tumour clearance by anti-CD133 CAR-NK cells relative to NKG2A-WT CAR-NK cells in a mouse model of acute myeloid leukaemia [117], and this strategy may be effective in potentiating the function of adoptively transferred NK cells in the lymph nodes of patients with B-cell malignancies. The gene discussed is KLRC1; the disease is acute myeloid leukemia.